XML 42 R31.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Collaboration and Licensing Revenue (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summarized Collaboration and Licensing Revenues | The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant collaboration or licensing agreement for the three and nine months ended September 30, 2016 and 2015.
| Three Months Ended September 30, 2016
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 4,843 |  |  | $ | 5,586 |  |  | $ | 10,429 |
Oragenics, Inc. | 262 |  |  | 294 |  |  | 556 |
Fibrocell Science, Inc. | 604 |  |  | 563 |  |  | 1,167 |
Genopaver, LLC | 68 |  |  | 1,625 |  |  | 1,693 |
S & I Ophthalmic, LLC | — |  |  | 2,782 |  |  | 2,782 |
OvaXon, LLC | — |  |  | 709 |  |  | 709 |
Intrexon Energy Partners, LLC | 625 |  |  | 4,230 |  |  | 4,855 |
Persea Bio, LLC | 125 |  |  | 208 |  |  | 333 |
Ares Trading S.A. | 1,597 |  |  | 719 |  |  | 2,316 |
Thrive Agrobiotics, Inc. | 46 |  |  | 379 |  |  | 425 |
Intrexon Energy Partners II, LLC | 500 |  |  | 372 |  |  | 872 |
Exotech Bio, Inc. | 139 |  |  | 82 |  |  | 221 |
Relieve Genetics, Inc. | 120 |  |  | 342 |  |  | 462 |
Intrexon T1D Partners, LLC | 276 |  |  | 511 |  |  | 787 |
AD Skincare, Inc. | 120 |  |  | 65 |  |  | 185 |
Other | 895 |  |  | 1,903 |  |  | 2,798 |
Total | $ | 10,220 |  |  | $ | 20,370 |  |  | $ | 30,590 |
| Three Months Ended September 30, 2015
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 645 |  |  | $ | 4,006 |  |  | $ | 4,651 |
Oragenics, Inc. | 4,868 |  |  | 332 |  |  | 5,200 |
Fibrocell Science, Inc. | 4,823 |  |  | 1,317 |  |  | 6,140 |
Genopaver, LLC | 68 |  |  | 993 |  |  | 1,061 |
S & I Ophthalmic, LLC | — |  |  | 1,193 |  |  | 1,193 |
OvaXon, LLC | — |  |  | 549 |  |  | 549 |
Intrexon Energy Partners, LLC | 625 |  |  | 3,185 |  |  | 3,810 |
Persea Bio, LLC | 125 |  |  | 297 |  |  | 422 |
Ares Trading S.A. | 1,597 |  |  | 260 |  |  | 1,857 |
Other | 7,841 |  |  | 2,002 |  |  | 9,843 |
Total | $ | 20,592 |  |  | $ | 14,134 |  |  | $ | 34,726 |
| Nine Months Ended September 30, 2016
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 6,687 |  |  | $ | 17,693 |  |  | $ | 24,380 |
Oragenics, Inc. | 786 |  |  | 1,083 |  |  | 1,869 |
Fibrocell Science, Inc. | 1,814 |  |  | 2,604 |  |  | 4,418 |
Genopaver, LLC | 205 |  |  | 4,703 |  |  | 4,908 |
S & I Ophthalmic, LLC | — |  |  | 6,326 |  |  | 6,326 |
OvaXon, LLC | — |  |  | 2,211 |  |  | 2,211 |
Intrexon Energy Partners, LLC | 1,875 |  |  | 11,180 |  |  | 13,055 |
Persea Bio, LLC | 375 |  |  | 613 |  |  | 988 |
Ares Trading S.A. | 4,791 |  |  | 2,148 |  |  | 6,939 |
Thrive Agrobiotics, Inc. | 138 |  |  | 1,171 |  |  | 1,309 |
Intrexon Energy Partners II, LLC | 1,500 |  |  | 816 |  |  | 2,316 |
Exotech Bio, Inc. | 278 |  |  | 82 |  |  | 360 |
Relieve Genetics, Inc. | 240 |  |  | 572 |  |  | 812 |
Intrexon T1D Partners, LLC | 554 |  |  | 543 |  |  | 1,097 |
AD Skincare, Inc. | 120 |  |  | 65 |  |  | 185 |
Other | 4,684 |  |  | 6,287 |  |  | 10,971 |
Total | $ | 24,047 |  |  | $ | 58,097 |  |  | $ | 82,144 |
| Nine Months Ended September 30, 2015
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 1,933 |  |  | $ | 11,769 |  |  | $ | 13,702 |
Oragenics, Inc. | 5,437 |  |  | 408 |  |  | 5,845 |
Fibrocell Science, Inc. | 5,719 |  |  | 4,500 |  |  | 10,219 |
Genopaver, LLC | 205 |  |  | 2,460 |  |  | 2,665 |
S & I Ophthalmic, LLC | — |  |  | 2,838 |  |  | 2,838 |
OvaXon, LLC | — |  |  | 1,855 |  |  | 1,855 |
Intrexon Energy Partners, LLC | 1,875 |  |  | 8,101 |  |  | 9,976 |
Persea Bio, LLC | 375 |  |  | 553 |  |  | 928 |
Ares Trading S.A. | 2,336 |  |  | 260 |  |  | 2,596 |
Other | 9,446 |  |  | 6,620 |  |  | 16,066 |
Total | $ | 27,326 |  |  | $ | 39,364 |  |  | $ | 66,690 |
Summary of Deferred Revenue | Deferred revenue consists of the following:
| September 30, 2016 |  | December 31, 2015
Upfront and milestone payments | $ | 309,126 |  |  | $ | 181,331 |
Prepaid research and development services | 7,057 |  |  | 10,938 |
Prepaid product and service revenues | 5,594 |  |  | 4,759 |
Other | 620 |  |  | 701 |
Total | $ | 322,397 |  |  | $ | 197,729 |
Current portion of deferred revenue | $ | 54,937 |  |  | $ | 35,366 |
Long-term portion of deferred revenue | 267,460 |  |  | 162,363 |
Total | $ | 322,397 |  |  | $ | 197,729 |
Summary of Deferred Revenue by Collaborator | The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement:
| September 30, 2016 |  | December 31, 2015
ZIOPHARM Oncology, Inc. | $ | 143,651 |  |  | $ | 30,338 |
Oragenics, Inc. | 8,027 |  |  | 8,813 |
Fibrocell Science, Inc. | 19,631 |  |  | 21,445 |
Genopaver, LLC | 2,045 |  |  | 2,250 |
Intrexon Energy Partners, LLC | 18,750 |  |  | 20,625 |
Persea Bio, LLC | 4,125 |  |  | 4,500 |
Ares Trading S.A. | 48,776 |  |  | 53,567 |
Thrive Agrobiotics, Inc. | 1,483 |  |  | 1,621 |
Intrexon Energy Partners II, LLC | 16,333 |  |  | 17,833 |
Exotech Bio, Inc. | 4,722 |  |  | — |
Relieve Genetics, Inc. | 4,093 |  |  | — |
Intrexon T1D Partners, LLC | 9,383 |  |  | — |
AD Skincare, Inc. | 4,213 |  |  | — |
Genten Therapeutics, Inc. | 4,523 |  |  | — |
CRS Bio, Inc. | 2,111 |  |  | — |
Other | 17,260 |  |  | 20,339 |
Total | $ | 309,126 |  |  | $ | 181,331 |

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of summarized revenues recognized for each significant collaboration and licensing agreement and aggregated nonsignificant collaborations and licensing agreements. + References No definition available. + Details
Name: | xon_CollaborationandLicensingRevenueTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amounts that comprise the deferred revenue by collaborator as of the balance sheet date. + References No definition available. + Details
Name: | xon_DeferredRevenueByCollaboratorDisclosureTableTextBlockTableTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration